


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): John G. Babish, et al.
Application No: 10/557,293
Confirmation No.: 9021
Art Unit: 1655
Filed: December 20, 2006
Title: ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS FOR
REDUCING INFLAMMATION AND THE TREATMENT OR
PREVENTION OF GASTRIC TOXICITY
Docket No.: 068911-0126
Confirmation No.: 9021

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the U.S. Postal Service via First Class Mail in an envelope addressed to: Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted (571) 273-8300 or filed via EFS-Web to the USPTO, on the date indicated below.

Date: August 31, 2010


Jacqueline Andreu

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313


TRANSMITTAL LETTER

Applicants enclose herewith for filing in connection with the above-referenced patent application the following documents:

- 1) Statement of Entity Status Change Notification Under 37 CFR § 1.27(g)(2) (1 page); and
- 2) Part B - Issue Fee Transmittal (entity status has been changed to Large entity; please see the enclosed Statement) (2 copies).

No costs are believed to be due in connection with the filing of the enclosed statement. The Commissioner is hereby authorized to charge the issue fees (based on LARGE entity status) or any required fees to Deposit Account No. 50-1133.

Respectfully submitted,
McDERMOTT WILL & EMERY LLP


Atabak R. Royace, Reg. No.: 59,037
McDERMOTT WILL & EMERY LLP
28 State Street
Boston, MA 02109
Telephone: (617) 535-4108
Facsimile: (617) 535-3800

Date: August 31, 2010